Literature DB >> 18339792

Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD.

Daiana Stolz1, Tobias Breidthardt, Mirjam Christ-Crain, Roland Bingisser, David Miedinger, Jörg Leuppi, Beat Mueller, Michael Tamm, Christian Mueller.   

Abstract

BACKGROUND: In patients with COPD, prognosis might be determined at least in part by the extent of cardiac stress induced by hypoxia and pulmonary arterial hypertension.
METHODS: B-type natriuretic peptide (BNP), a quantitative marker of cardiac stress, was determined in 208 consecutive patients presenting to the emergency department with an acute exacerbation of COPD (AECOPD). The accuracy of BNP to predict death at a 2-year follow-up was evaluated as the primary end point. The need for intensive care and in-hospital mortality were determined as secondary end points.
RESULTS: BNP levels were significantly elevated during the acute exacerbation compared to recovery (65 pg/mL; interquartile range [IQR], 34 to 189 pg/mL; vs 45 pg/mL; IQR, 25 to 85 pg/mL; p < 0.001), particularly in those patients requiring ICU treatment (105 pg/mL; IQR, 66 to 553 pg/mL; vs 60 pg/mL; IQR, 31 to 169 pg/mL; p = 0.007). In multivariate Cox regression analysis, BNP accurately predicted the need for ICU care (hazard ratio, 1.13; 95% confidence interval [CI], 1.03 to 1.24 for an increase in BNP of 100 pg/mL; p = 0.008). In a receiver operating characteristic analysis to evaluate the potential of BNP levels to predict short-term and long-term mortality rates, areas under the curve were 0.55 (SD, 0.71; 95% CI, 0.41 to 0.68) and 0.56 (SD, 0.53; 95% CI, 0.45 to 0.66, respectively).
CONCLUSIONS: In patients with AECOPD, BNP levels independently predict the need for intensive care. However, BNP levels failed to adequately predict short-term and long-term mortality rates in AECOPD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339792     DOI: 10.1378/chest.07-1959

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.

Authors:  Wassim W Labaki; Meng Xia; Susan Murray; Jeffrey L Curtis; R Graham Barr; Surya P Bhatt; Eugene R Bleecker; Nadia N Hansel; Christopher B Cooper; Mark T Dransfield; J Michael Wells; Eric A Hoffman; Richard E Kanner; Robert Paine; Victor E Ortega; Stephen P Peters; Jerry A Krishnan; Russell P Bowler; David J Couper; Prescott G Woodruff; Fernando J Martinez; Carlos H Martinez; MeiLan K Han
Journal:  Respir Med       Date:  2018-06-05       Impact factor: 3.415

2.  The Correlation of Serum Brain Natriuretic Peptide and Interleukin-6 with Quality of Life Using the Chronic Obstructive Pulmonary Disease Assessment Test.

Authors:  Hassan Ghobadi; Mohammad Reza Aslani; Adalat Hosseinian; Esmaeil Farzaneh
Journal:  Med Princ Pract       Date:  2017-11-02       Impact factor: 1.927

3.  Geometry of the randomized evidence for treatments of pulmonary hypertension.

Authors:  Adriano R Tonelli; Joe Zein; John P A Ioannidis
Journal:  Cardiovasc Ther       Date:  2013-12       Impact factor: 3.023

Review 4.  Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations.

Authors:  Kenan Yalta; Tulin Yalta; Muhammet Gurdogan; Orkide Palabıyık; Ertan Yetkın
Journal:  Curr Allergy Asthma Rep       Date:  2020-04-28       Impact factor: 4.806

5.  Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi.

Authors:  Maria G Matera; Luigino Calzetta; Daniela Passeri; Francesco Facciolo; Erino A Rendina; Clive Page; Mario Cazzola; Augusto Orlandi
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

6.  Impact of cardiopulmonary complications of lung cancer surgery on long-term outcomes.

Authors:  Takashi Nojiri; Masayoshi Inoue; Yukiyasu Takeuchi; Hajime Maeda; Yasushi Shintani; Noriyoshi Sawabata; Toshimitsu Hamasaki; Meinoshin Okumura
Journal:  Surg Today       Date:  2014-09-19       Impact factor: 2.549

Review 7.  Interpretation and use of natriuretic peptides in non-congestive heart failure settings.

Authors:  Shih-Hung Tsai; Yen-Yue Lin; Shi-Jye Chu; Ching-Wang Hsu; Shu-Meng Cheng
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

8.  Influence of preoperative serum N-terminal pro-brain type natriuretic peptide on the postoperative outcome and survival rates of coronary artery bypass patients.

Authors:  Thomas Schachner; Dominik Wiedemann; Hannes Fetz; Guenther Laufer; Alfred Kocher; Nikolaos Bonaros
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

9.  Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.

Authors:  Anant R C Patel; Beverly S Kowlessar; Gavin C Donaldson; Alex J Mackay; Richa Singh; Siobhan N George; Davinder S Garcha; Jadwiga A Wedzicha; John R Hurst
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

10.  NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study.

Authors:  Arne Didrik Høiseth; Torbjørn Omland; Tor-Arne Hagve; Pål H Brekke; Vidar Søyseth
Journal:  Respir Res       Date:  2012-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.